Description du poste
TLDR: Cryonics should be considered as part of a diversified portfolio of altruistic projects. I estimate, using ~3% chance of revival and a modest post-revival lifespan (~20,000 years), that current biopreservation is roughly on par with top GiveWell charities in terms of QALYs per dollar. Scaled up, it could plausibly be dozens of times better. There are various complications, of course, but it still seems reasonable that cryonics complements rather than competes with things like AI-safety work. It may even ease pressure to race toward superintelligence as people’s only hope of not dying.
Meta: I’m Max Harms, long-time researcher at MIRI,[1] rationalist, EA, and cryonics enthusiast. After doing a deep-dive on Nectome, a brain preservation startup, they hired me to write some additional pieces on cryonics (by which I mean both “traditional cryonics” and the aldehyde-based preservation used by Nectome).[2] The ideas in this essay are ones I have believed for many years, and I was the one who pitched the idea to Nectome.
Part 1: DiversificationCommon wisdom in investment circles is to have a diversified portfolio — to not put all your eggs in one basket. This is wise for two reasons:
• Money is not utility. The difference between being broke and having a million dollars is much, much bigger than the difference between having 100 million and 101 million. Double-or-nothing usually has negative expected value, even if it’s neutral in expected money. We often assume that humans are logarithmic in how much they value money, even though that’s an oversimplification, because it’s a reasonably simple way to reflect the nonlinearity.• Opportunities for investment are usually limited in how much money they can absorb, and that investment cap is generally above what you can currently invest (unless you’re already wealthy). Since the returns for the ultra-wealthy are capped, it’s less important to become wealthy as soon as possible and relatively more important to become wealth